Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum-based chemotherapeutics.

Described herein is anhydrous sodium thiosulfate, methods for synthesizing anhydrous sodium thiosulfate, pharmaceutical compositions thereof, and methods of treating ototoxicity. Anhydrous sodium thiosulfate is synthesized from sodium sulfite, sulfur, and cetylpyridinium chloride. The anhydrous sodium thiosulfate is formulated into a pharmaceutical composition comprising a buffer and solvent. These compositions are useful for eliminating or reducing ototoxicity in pediatric patients receiving platinum based chemotherapeutics.

Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

A method and a facility for wet-scrubbing sulfur dioxide to produce, for example, potassium thiosulfate or ammonium thiosulfate. The facility includes a multi-section vessel having multiple horizontally disposed stages where a preceding stage passes partially-scrubbed waste gas to a succeeding stage. Each stage has a scrubber mechanism to scrub waste gas with circulating fluid that successively reduces waste gas concentration before atmospheric discharge. The scrubber mechanism may include a packing to facilitate absorption of waste gas by the fluid, a sump disposed at the output of the stage to receive fluid as it drains from the packing, and a circulation pump to circulate fluid from the sump to its packing and to cascade at least a portion of the fluid back to a preceding stage. A portion of the fluid is extracted from the facility and reacted in a reaction vessel with a cation to produce ammonium thiosulfate or potassium thiosulfate.

A method and a facility for wet-scrubbing sulfur dioxide to produce, for example, potassium thiosulfate or ammonium thiosulfate. The facility includes a multi-section vessel having multiple horizontally disposed stages where a preceding stage passes partially-scrubbed waste gas to a succeeding stage. Each stage has a scrubber mechanism to scrub waste gas with circulating fluid that successively reduces waste gas concentration before atmospheric discharge. The scrubber mechanism may include a packing to facilitate absorption of waste gas by the fluid, a sump disposed at the output of the stage to receive fluid as it drains from the packing, and a circulation pump to circulate fluid from the sump to its packing and to cascade at least a portion of the fluid back to a preceding stage. A portion of the fluid is extracted from the facility and reacted in a reaction vessel with a cation to produce ammonium thiosulfate or potassium thiosulfate.

This invention relates to production of an aqueous solution containing ammonium thiosulfate from a feed gas containing hydrogen sulfide (H.sub.2S) and ammonia (NH.sub.3). Sufficient separation of feed gas H.sub.2S from NH.sub.3 is achieved by controlling individual NH.sub.3 and H.sub.2S absorption mass-transfer rates in a single co-current stage, whereby a first gas contacts a first liquid containing ammonium bisulfite (ABS). Substantially more NH.sub.3 is absorbed than H.sub.2S, converting ABS to diammonium sulfite (DAS). A portion of DAS reacts with a sufficiently small portion of H.sub.2S to produce ATS and leaves as a second liquid stream. A larger portion of H.sub.2S leaves as a second gas stream. The second gas stream is oxidized to sulfur dioxide (SO.sub.2) comprising a third gas stream. The third gas stream contacts the second aqueous stream in a second contact stage whereby DAS in the second liquid stream is converted to ABS and returned to the first contacting zone.

This invention relates to production of an aqueous solution containing ammonium thiosulfate from a feed gas containing hydrogen sulfide (H.sub.2S) and ammonia (NH.sub.3). Sufficient separation of feed gas H.sub.2S from NH.sub.3 is achieved by controlling individual NH.sub.3 and H.sub.2S absorption mass-transfer rates in a single co-current stage, whereby a first gas contacts a first liquid containing ammonium bisulfite (ABS). Substantially more NH.sub.3 is absorbed than H.sub.2S, converting ABS to diammonium sulfite (DAS). A portion of DAS reacts with a sufficiently small portion of H.sub.2S to produce ATS and leaves as a second liquid stream. A larger portion of H.sub.2S leaves as a second gas stream. The second gas stream is oxidized to sulfur dioxide (SO.sub.2) comprising a third gas stream. The third gas stream contacts the second aqueous stream in a second contact stage whereby DAS in the second liquid stream is converted to ABS and returned to the first contacting zone.

Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.